NanJing Pharmaceutical Co Ltd
Nanjing Pharmaceutical Group Company Limited engages in the drug distribution businesses in China. It also involved in the wholesale and retail of medical device distribution; pharmaceutical logistics; and internet drug retail business. The company was formerly known as NanJing Pharmaceutical Company Limited and change its name to Nanjing Pharmaceutical Group Company Limited in December 2025. Nan… Read more
NanJing Pharmaceutical Co Ltd (600713) - Total Assets
Latest total assets as of September 2025: CN¥34.05 Billion CNY
Based on the latest financial reports, NanJing Pharmaceutical Co Ltd (600713) holds total assets worth CN¥34.05 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
NanJing Pharmaceutical Co Ltd - Total Assets Trend (1994–2024)
This chart illustrates how NanJing Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
NanJing Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
NanJing Pharmaceutical Co Ltd's total assets of CN¥34.05 Billion consist of 90.7% current assets and 9.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 14.9% |
| Accounts Receivable | CN¥15.91 Billion | 51.9% |
| Inventory | CN¥6.29 Billion | 20.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥234.12 Million | 0.8% |
| Goodwill | CN¥72.17 Million | 0.2% |
Asset Composition Trend (1994–2024)
This chart illustrates how NanJing Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NanJing Pharmaceutical Co Ltd's current assets represent 90.7% of total assets in 2024, an increase from 75.6% in 1994.
- Cash Position: Cash and equivalents constituted 14.9% of total assets in 2024, up from 13.7% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1994.
- Asset Diversification: The largest asset category is accounts receivable at 51.9% of total assets.
NanJing Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of NanJing Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.55 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.07 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367
|
China | CN¥1.52 Billion |
NanJing Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - NanJing Pharmaceutical Co Ltd generates 1.75x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, NanJing Pharmaceutical Co Ltd generates $ 1.86 in net profit.
NanJing Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.45 | 1.50 | 1.23 |
| Quick Ratio | 1.14 | 1.20 | 0.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥9.56 Billion | CN¥ 9.91 Billion | CN¥ 3.96 Billion |
NanJing Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between NanJing Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.02 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 8.0% |
| Total Assets | CN¥30.67 Billion |
| Market Capitalization | $407.93 Million USD |
Valuation Analysis
Below Book Valuation: The market values NanJing Pharmaceutical Co Ltd's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: NanJing Pharmaceutical Co Ltd's assets grew by 8.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for NanJing Pharmaceutical Co Ltd (1994–2024)
The table below shows the annual total assets of NanJing Pharmaceutical Co Ltd from 1994 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥30.67 Billion | +7.97% |
| 2023-12-31 | CN¥28.41 Billion | -10.24% |
| 2022-12-31 | CN¥31.65 Billion | +22.27% |
| 2021-12-31 | CN¥25.89 Billion | +10.58% |
| 2020-12-31 | CN¥23.41 Billion | +6.57% |
| 2019-12-31 | CN¥21.97 Billion | +12.33% |
| 2018-12-31 | CN¥19.55 Billion | +22.79% |
| 2017-12-31 | CN¥15.93 Billion | +14.06% |
| 2016-12-31 | CN¥13.96 Billion | +10.85% |
| 2015-12-31 | CN¥12.59 Billion | +10.85% |
| 2014-12-31 | CN¥11.36 Billion | +17.75% |
| 2013-12-31 | CN¥9.65 Billion | +4.58% |
| 2012-12-31 | CN¥9.23 Billion | +2.24% |
| 2011-12-31 | CN¥9.02 Billion | +7.77% |
| 2010-12-31 | CN¥8.37 Billion | +28.48% |
| 2009-12-31 | CN¥6.52 Billion | +29.22% |
| 2008-12-31 | CN¥5.04 Billion | +0.89% |
| 2007-12-31 | CN¥5.00 Billion | +35.58% |
| 2006-12-31 | CN¥3.69 Billion | +10.77% |
| 2005-12-31 | CN¥3.33 Billion | +6.21% |
| 2004-12-31 | CN¥3.13 Billion | +19.17% |
| 2003-12-31 | CN¥2.63 Billion | +44.80% |
| 2002-12-31 | CN¥1.82 Billion | +55.24% |
| 2001-12-31 | CN¥1.17 Billion | -4.82% |
| 2000-12-31 | CN¥1.23 Billion | +29.92% |
| 1999-12-31 | CN¥946.18 Million | +9.10% |
| 1998-12-31 | CN¥867.23 Million | +88.23% |
| 1997-12-31 | CN¥460.74 Million | +5.89% |
| 1996-12-31 | CN¥435.11 Million | +59.90% |
| 1995-12-31 | CN¥272.12 Million | +3.22% |
| 1994-12-31 | CN¥263.64 Million | -- |